<DOC>
	<DOCNO>NCT00915694</DOCNO>
	<brief_summary>RATIONALE : Nelfinavir mesylate may stop growth tumor cell block enzymes need cell growth . Radiation therapy use high energy x-ray kill tumor cell . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving nelfinavir mesylate together radiation therapy temozolomide may kill tumor cell . PURPOSE : This phase I trial study side effect best dose nelfinavir mesylate give together radiation therapy temozolomide treat patient glioblastoma multiforme .</brief_summary>
	<brief_title>Nelfinavir Mesylate , Radiation Therapy , Temozolomide Treating Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose nelfinavir mesylate give concurrently radiotherapy temozolomide follow temozolomide alone patient glioblastoma multiforme . - Determine safety dose-limiting toxicity regimen patient . Secondary - Determine progression-free survival ( PFS ) overall survival ( OS ) patient treat regimen . - Compare observed median value PFS OS obtain study historical median value 6.9 month 14.6 month , respectively . OUTLINE : This dose-escalation study nelfinavir mesylate . Patients receive oral nelfinavir mesylate twice daily begin 7-10 day initiation chemoradiotherapy continue completion chemoradiotherapy . Patients undergo radiotherapy daily 5 day week receive concurrent oral temozolomide daily 6 week . Beginning 4 week completion nelfinavir mesylate chemoradiotherapy , patient receive oral temozolomide alone daily day 1-5 . Treatment temozolomide repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm WHO grade IV supratentorial astrocytoma ( glioblastoma multiforme ) Newly diagnose disease Has undergone maximal surgical resection PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Serum creatinine &lt; 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2 time ULN Serum bilirubin &lt; 1.5 mg/dL No known HIV infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior cranial radiotherapy More 30 day since prior investigational agent No concurrent investigational agent No concurrent use follow drug : Antiarrhythmics ( i.e. , amiodarone quinidine ) Antimycobacterials ( i.e. , rifampin ) Ergot derivative ( i.e. , dihydroergotamine , ergonovine , ergotamine , methylergonovine ) Herbal product ( i.e. , St. John 's wort ) HMGCoA reductase inhibitor ( i.e. , lovastatin simvastatin ) Neuroleptics ( i.e. , pimozide ) Sedatives and/or hypnotic ( i.e. , midazolam triazolam ) Concurrent corticosteroid allow provide dose stable decrease ≥ 14 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult glioblastoma</keyword>
</DOC>